Association between non-medical cannabis legalization and alcohol sales: Quasi-experimental evidence from Canada.

Alcohol Canada Non-medical cannabis legalization Quasi-experiment

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 Apr 2024
Historique:
received: 16 10 2023
revised: 04 02 2024
accepted: 18 02 2024
pubmed: 10 3 2024
medline: 10 3 2024
entrez: 9 3 2024
Statut: ppublish

Résumé

There is increasing interest in understanding the impact of non-medical cannabis legalization on use of other substances, especially alcohol. Evidence on whether cannabis is a substitute or complement for alcohol is both mixed and limited. This study provides the first quasi-experimental evidence on the impact of Canada's legalization of non-medical cannabis on beer and spirits sales. We used the interrupted time series design and monthly data on beer sales between January 2012 and February 2020 and spirits sales between January 2016 and February 2020 across Canada to investigate changes in beer and spirits sales following Canada's cannabis legalization in October 2018. We examined changes in total sales, nationally and in individual provinces, as well as changes in sales of bottled, canned and kegged beer. Canada-wide beer sales fell by 96 hectoliters per 100,000 population (p=0.011) immediately after non-medical cannabis legalization and by 4 hectoliters per 100,000 population (p>0.05) each month thereafter for an average monthly reduction of 136 hectoliters per 100,000 population (p<0.001) post-legalization. However, the legalization was associated with no change in spirits sales. Beer sales reduced in all provinces except the Atlantic provinces. By beer type, the legalization was associated with declines in sales of canned and kegged beer but there was no reduction in sales of bottled beer. Non-medical cannabis legalization was associated with a decline in beer sales in Canada, suggesting substitution of non-medical cannabis for beer. However, there was no change in spirits sales following the legalization.

Sections du résumé

BACKGROUND BACKGROUND
There is increasing interest in understanding the impact of non-medical cannabis legalization on use of other substances, especially alcohol. Evidence on whether cannabis is a substitute or complement for alcohol is both mixed and limited. This study provides the first quasi-experimental evidence on the impact of Canada's legalization of non-medical cannabis on beer and spirits sales.
METHODS METHODS
We used the interrupted time series design and monthly data on beer sales between January 2012 and February 2020 and spirits sales between January 2016 and February 2020 across Canada to investigate changes in beer and spirits sales following Canada's cannabis legalization in October 2018. We examined changes in total sales, nationally and in individual provinces, as well as changes in sales of bottled, canned and kegged beer.
RESULTS RESULTS
Canada-wide beer sales fell by 96 hectoliters per 100,000 population (p=0.011) immediately after non-medical cannabis legalization and by 4 hectoliters per 100,000 population (p>0.05) each month thereafter for an average monthly reduction of 136 hectoliters per 100,000 population (p<0.001) post-legalization. However, the legalization was associated with no change in spirits sales. Beer sales reduced in all provinces except the Atlantic provinces. By beer type, the legalization was associated with declines in sales of canned and kegged beer but there was no reduction in sales of bottled beer.
CONCLUSIONS CONCLUSIONS
Non-medical cannabis legalization was associated with a decline in beer sales in Canada, suggesting substitution of non-medical cannabis for beer. However, there was no change in spirits sales following the legalization.

Identifiants

pubmed: 38460325
pii: S0376-8716(24)00058-9
doi: 10.1016/j.drugalcdep.2024.111137
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111137

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest No conflict was declared.

Auteurs

Shweta Mital (S)

College of Pharmacy, University of Manitoba, Winnipeg, Canada.

Lisa Bishop (L)

School of Pharmacy, Memorial University of Newfoundland, St. John's, Canada.

Shawn Bugden (S)

School of Pharmacy, Memorial University of Newfoundland, St. John's, Canada.

Paul Grootendorst (P)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.

Hai V Nguyen (HV)

School of Pharmacy, Memorial University of Newfoundland, St. John's, Canada. Electronic address: hvnguyen@mun.ca.

Classifications MeSH